Amarin reported preliminary fourth-quarter product sales of $117 million, topping consensus estimates of $110 million by 6.4%. The company also provided preliminary fiscal 2025 revenue guidance of $460 million to $470 million, compared with analysts’ consensus of $445 million. These better-than-expected figures helped drive a 17% stock rally on the day of the announcement.

For Q4, Amarin generated positive operating cash flow of $15 million, reversing a cash burn trend seen earlier in the year. The company attributed the improvement to a series of cost management measures, including a 20% reduction in non-commercial headcount and renegotiation of key supplier contracts, which are expected to yield $25 million in annual savings starting in mid-2026.

Amarin’s flagship icosapent ethyl franchise has now been prescribed more than 25 million times worldwide. Building on the REDUCE-IT cardiovascular outcomes trial of 8,179 patients—where VASCEPA showed a 25% relative reduction in major adverse cardiovascular events versus placebo—the company secured an exclusive license with Recordati to commercialize VAZKEPA in 59 European markets through 2039. VASCEPA/VAZKEPA is commercially available in over 20 countries.

Recent FDA breakthrough therapy designations for novel ApoC-III injectables have heightened focus on severe hypertriglyceridemia (TG ≥500 mg/dL), but existing payor-driven step-therapy programs are likely to position VASCEPA as the preferred first-line option. Historical precedent from the 2015 PCSK9 inhibitor launch—where step-therapy requirements drove a sustained 15% annual growth in ezetimibe prescriptions—suggests similar tailwinds for Amarin’s cost-effective, broadly reimbursed agent.